Table 2.
Characteristics of the study population at enrollment.
| Variables | Sarcoidosis Patients with PE (n = 15) |
Sarcoidosis Patients without PE (n = 241) |
p-Value |
|---|---|---|---|
| Sarcoidosis Organ Involvement | |||
| Lymph node involvement (n, %) | 13 (87%) | 205 (85%) | p > 0.05 |
| Lung (n, %) | 11 (73%) | 187 (77%) | p > 0.05 |
| Renal/Hypercalciuria (n, %) | 5 (33%) | 74 (31%) | p > 0.05 |
| Cutaneous (n, %) | 4 (26%) | 54 (22%) | p > 0.05 |
| Osteoarticular (n, %) | 2 (13%) | 36 (15%) | p > 0.05 |
| Abdominal (n, %) | 2 (13%) | 25 (10%) | p > 0.05 |
| Cardiac (n, %) | 0 (0%) | 9 (3%) | p > 0.05 |
| Neurological (n, %) | 1 (7%) | 7 (3%) | p > 0.05 |
| Ocular (n, %) | 1 (7%) | 7 (3%) | p > 0.05 |
| Lofgren’s syndrome (n, %) | 1 (7%) | 5 (2%) | p > 0.05 |
| Blood Tests | |||
| ACE (U/L) (mean ± SD) | 43.73 ± 45.17 | 38.92 ± 34.65 | p > 0.05 |
| D-dimer (500 ng/mL FEU) | 279 ± 184 | 301 ± 162 | p > 0.05 |
| CD4/CD8 lymphocytes (mean ± SD) | 2.06 ± 1.21 | 3.68 ± 1.33 | p = 0.013 |
| Thrombophilic screening positivity (n, %) | 5 (33%) | 16 (6%) | p > 0.05 |
| Antiphospholipid antibodies positivity (n, %) | 7 (46%) | 23 (9%) | p = 0.026 |
| Pulmonary Function Tests | |||
| FVC (mean ± SD) | 102.78 ± 18.16 | 104.79 ± 18.03 | p > 0.05 |
| FEV1 (mean ± SD) | 97.07 ± 15.70 | 96.90 ± 20.17 | p > 0.05 |
| IT (mean ± SD) | 79.57 ± 7.83 | 76.79 ± 9.33 | p > 0.05 |
| DLCO (mean ± SD) | 88.53 ± 20.43 | 86.83 ± 21.41 | p > 0.05 |
Legend. n = number of patients, % = percentage of patients; ACE = angiotensin converting enzyme, FEU = Fibrinogen Equivalent Units, FVC = functional vital capacity, FEV1 = forced expiratory volume in 1 s, IT = Tiffenau index = forced expiratory volume in 1 s/functional vital capacity, DLCO = diffusion capacity of carbon monoxide.